They can both be obtained from food sources and offer potential health benefits
There is good reason for the excitement surrounding the new glucagon-like peptide-1 (GLP-1) receptor- and glucose-dependent insulinotropic polypeptide (GIP) receptor-targeted therapies that will come into the market this year and next, say diabetes and obesity investigators who will be featured speakers at the 2026 Scientific Sessions of the American Diabetes Association (ADA)
They use peptides that mimic satiety hormones, which target the areas of the brain that regulate appetite
This isn't optional, not negotiable, and not subject to the regulatory uncertainties affecting other aspects of GLP-1 compounding
I finally felt better last night because I started cooking my own food again
Both medications can cause elevated heart rate, elevated blood pressure, insomnia, appetite suppression, anxiety, and irritability